NVS icon

Novartis

123.12 USD
-0.19
0.15%
At close Updated Sep 16, 10:55 AM EDT
1 day
-0.15%
5 days
-3.28%
1 month
-0.72%
3 months
4.26%
6 months
9.71%
Year to date
26.74%
1 year
5.28%
5 years
37.03%
10 years
40.6%
 

About: Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Employees: 75,883

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

61% more first-time investments, than exits

New positions opened: 116 | Existing positions closed: 72

14% more funds holding in top 10

Funds holding in top 10: 14 [Q1] → 16 (+2) [Q2]

1% more funds holding

Funds holding: 1,338 [Q1] → 1,354 (+16) [Q2]

4% more repeat investments, than reductions

Existing positions increased: 488 | Existing positions reduced: 468

3% more capital invested

Capital invested by funds: $15.4B [Q1] → $15.9B (+$500M) [Q2]

0.37% less ownership

Funds ownership: 6.58% [Q1] → 6.21% (-0.37%) [Q2]

19% less call options, than puts

Call options by funds: $269M | Put options by funds: $331M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$118
4% downside
Avg. target
$118
4% downside
High target
$118
4% downside

1 analyst rating

positive
0%
neutral
0%
negative
100%
Goldman Sachs
James Quigley
$118
Sell
Downgraded
12 Sep 2025

Financial journalist opinion

Based on 26 articles about NVS published over the past 30 days

Positive
Benzinga
23 hours ago
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa Therapeutics Inc. GLUE stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Positive
Reuters
yesterday
Novartis, Monte Rosa strike $5.7 billion drug development deal
Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases.
Novartis, Monte Rosa strike $5.7 billion drug development deal
Negative
Barrons
3 days ago
Novartis Catches a ‘Sell.' Goldman Sachs Says the Stock Is Overvalued.
Only 20% of analysts tracked by FactSet rate the stock at Buy.
Novartis Catches a ‘Sell.' Goldman Sachs Says the Stock Is Overvalued.
Neutral
Reuters
5 days ago
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, according to an analysis by brokerage Morningstar.
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
Neutral
Zacks Investment Research
5 days ago
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Negative
Zacks Investment Research
5 days ago
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Positive
Investors Business Daily
7 days ago
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company for $1.4 billion.
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Positive
Invezz
7 days ago
Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit
Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be acquired by Swiss pharmaceutical major Novartis for approximately $1.4 billion. Tourmaline shares jumped nearly 58%, trading at $48 per share, compared with Monday's closing price of $30.18.
Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit
Neutral
MarketBeat
7 days ago
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver
GLP-1 drugs are taking much oxygen out of the biotechnology trade. However, many investors have been eyeing other areas in the sector, particularly cancer research.
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver
Positive
Barrons
7 days ago
This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.
Novartis agrees to acquire Tourmaline Bio in an all-cash deal worth around $1.4 billion.
This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.
Charts implemented using Lightweight Charts™